Related Experiment Video
Updated: Jul 1, 2026
08:59
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
Published on: July 16, 2021
The endocannabinoid system in amyotrophic lateral sclerosis.
Lynsey G Bilsland1, Linda Greensmith
1Molecular NeuroPathobiology, Cancer Research UK, 44 Lincoln's Inn Fields, London, UK.
Current Pharmaceutical Design
|September 11, 2008
Summary
Cannabinoids show promise for treating Amyotrophic Lateral Sclerosis (ALS) by targeting multiple neurotoxic pathways. Activating CB2 receptors may reduce inflammation and microglial activation, offering potential therapeutic benefits for ALS patients.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron loss.
- Pathogenesis involves excitotoxicity, inflammation, and oxidative stress, with non-neuronal cells like microglia playing a key role.
- Current treatments, such as Riluzole, offer limited efficacy.
Purpose of the Study:
- To review the therapeutic potential of cannabinoids and the endocannabinoid system in ALS treatment.
- To explore how cannabinoids target multiple neurotoxic pathways relevant to ALS pathogenesis.
- To discuss recent findings on CB2 receptor activation strategies for ALS.
Main Methods:
- Review of existing literature on cannabinoids, endocannabinoid system, and ALS.
- Analysis of mechanisms of action for cannabinoids, including CB1 and CB2 receptor activation.
- Examination of studies investigating cannabinoid efficacy in ALS models.
Main Results:
- Cannabinoids possess anti-glutamatergic, anti-inflammatory, and antioxidant properties.
- CB1 receptor activation may reduce excitotoxicity by inhibiting glutamate release.
- CB2 receptor activation can decrease neuroinflammation by modulating microglial activity.
Conclusions:
- Cannabinoids offer a multi-targeted therapeutic approach for ALS.
- Targeting the endocannabinoid system, particularly CB2 receptors, presents a promising strategy for ALS treatment.
- Further research into cannabinoid-based therapies is warranted for neurodegenerative conditions like ALS.
More Related Videos
Related Concept Videos
01:26Cross-bridge Cycle
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.